









市場行情
/
股票
/
nasdaq-vyne
/

Vyne Therapeutics Inc

VYNE

0.586USD

+0.001+0.21%

收盤 12/19, 16:00（美東）報價延遲15分鐘

18.62M總市值

虧損本益比TTM



Vyne Therapeutics Inc

0.586

+0.001+0.21%

概覽公司財務分析

概覽

公司

財務

分析

關於 Vyne Therapeutics Inc 公司

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Vyne Therapeutics Inc簡介



公司代碼VYNE

公司名稱Vyne Therapeutics Inc

上市日期Jan 25, 2018

CEODomzalski (David)

員工數量13

證券類型Ordinary Share

年結日Jan 25

公司地址685 Route 202/206 N., Suite 301

城市BRIDGEWATER

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編08807

電話18007757936

網址https://vynetherapeutics.com/

公司代碼VYNE

上市日期Jan 25, 2018

CEODomzalski (David)

Vyne Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

112.77K

-2.94%

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

54.74K

+41.39%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

44.30K

+57.33%

Mr. Steven L. Basta

Independent Director

7.45K

Ms. Sharon Barbari

Independent Director

Mr. David Domzalski

President, Chief Executive Officer, Director

Ms. Elisabeth A. Sandoval Little

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Tyler Zeronda

Chief Financial Officer, Treasurer

112.77K

-2.94%

Ms. Mutya Fonte Harsch, J.D.

Chief Legal Officer, General Counsel, Secretary

54.74K

+41.39%

Mr. Patrick G. Lepore

Lead Independent Director

51.47K

Dr. Iain Stuart, Ph.D.

Chief Scientific Officer

44.30K

+57.33%

Mr. Steven L. Basta

Independent Director

7.45K

Ms. Sharon Barbari

Independent Director

收入明細

單位: USD更新時間: 10月6日週一

FY2024

FY2023

FY2022

FY2021

FY2020

業務USD

名稱

營收

佔比

Royalty revenues

501.00K

0.00%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Royalty revenues

501.00K

0.00%

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

Access Industries, Inc.

3.35%

Baker Bros. Advisors LP

2.56%

Delaware Street Capital, L.L.C.

2.09%

Acorn Capital Advisors, LLC

1.76%

Shay Capital LLC

1.48%

其他

88.75%

持股股東

佔比

Access Industries, Inc.

3.35%

Baker Bros. Advisors LP

2.56%

Delaware Street Capital, L.L.C.

2.09%

Acorn Capital Advisors, LLC

1.76%

Shay Capital LLC

1.48%

其他

88.75%

股東類型

持股股東

佔比

Hedge Fund

8.41%

Corporation

3.35%

Investment Advisor

2.99%

Investment Advisor/Hedge Fund

2.19%

Individual Investor

1.31%

Research Firm

0.45%

其他

81.29%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

8.51M

25.77%

-898.65K

2025Q2

9.46M

56.76%

-1.30M

2025Q1

9.36M

56.20%

-1.38M

2024Q4

9.37M

63.49%

-533.87K

2024Q3

8.98M

61.30%

-594.32K

2024Q2

9.65M

66.73%

+287.65K

2024Q1

9.64M

67.66%

+101.95K

2023Q4

101

10.22M

72.71%

+4.63M

2023Q3

117

471.27K

14.37%

-340.06K

2023Q2

135

501.83K

15.37%

-314.68K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Access Industries, Inc.

1.12M

4.38%

Feb 14, 2025

Delaware Street Capital, L.L.C.

696.47K

2.73%

Sep 30, 2024

Acorn Capital Advisors, LLC

736.57K

2.89%

-49.37K

-6.28%

Jun 30, 2025

Ikarian Capital LLC

290.00K

1.14%

+290.00K

Jun 30, 2025

The Vanguard Group, Inc.

496.30K

1.95%

+20.65K

+4.34%

Jun 30, 2025

Domzalski (David T)

107.13K

0.42%

-12.68K

-10.58%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

iShares Micro-Cap ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

公告日期

類型

比率

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 10, 2023

Merger

18→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

Feb 12, 2021

Merger

4→1

常見問題

Vyne Therapeutics Inc的前五大股東是誰？



Vyne Therapeutics Inc的前五大股東如下：
Access Industries, Inc.
持有股份：1.12M
佔總股份比例：4.38%。
Delaware Street Capital, L.L.C.
持有股份：696.47K
佔總股份比例：2.73%。
Acorn Capital Advisors, LLC
持有股份：736.57K
佔總股份比例：2.89%。
Ikarian Capital LLC
持有股份：290.00K
佔總股份比例：1.14%。
The Vanguard Group, Inc.
持有股份：496.30K
佔總股份比例：1.95%。